Makoto Naganuma, Yoko Yokoyama, Satoshi Motoya, Kenji Watanabe, Koji Sawada, Fumito Hirai, Takayuki Yamamoto, Hiroyuki Hanai, Teppei Omori, Takanori Kanai & Toshifumi Hibi, Journal of Gastroenterology volume 55, pages390–400 (2020)

Apheresis was well tolerated as maintenance therapy for UC although the cumulative clinical remission rate at 12 months was comparable between the apheresis and control groups.

Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter https://link.springer.com/article/10.1007/s00535-019-01651-0#group-1

Bruce E Sands ¹, Seymour Katz, Douglas C Wolf, Brian G Feagan, Tao Wang, Lisa-Marie Gustofson, Cindy Wong, Margaret K Vandervoort, Stephen Hanauer, Gut. 2013 Sep;62(9):1288-94.

GMA was well tolerated, but this study did not demonstrate its effectiveness over a sham procedure in inducing clinical remission or response in patients with moderate to severe CD.

https://pubmed.ncbi.nlm.nih.gov/22760005/